| Imran Q Cheema, MD | |
|
2620 N Westwood Blvd, Poplar Bluff, MO 63901-3396 | |
| (573) 686-3937 | |
| (573) 686-3958 |
| Full Name | Imran Q Cheema |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 33 Years |
| Location | 2620 N Westwood Blvd, Poplar Bluff, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316992340 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 2002030172 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centerpoint Medical Center | Independence, MO | Hospital |
| New Liberty Hospital District | Liberty, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pandc Healthcare Llc | 3779861109 | 43 |
| New Liberty Hospital Corporation | 9931166618 | 95 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20031111000818 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Entity Name | New Liberty Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669734661 PECOS PAC ID: 9931166618 Enrollment ID: O20120918000321 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Entity Name | Cole Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144578659 PECOS PAC ID: 0648420810 Enrollment ID: O20121024000296 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Entity Name | Butler Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982056545 PECOS PAC ID: 6608164561 Enrollment ID: O20161007001160 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Entity Name | P&c Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124575923 PECOS PAC ID: 3779861109 Enrollment ID: O20170302001808 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Imran Q Cheema, MD 2210 Barron Rd, Poplar Bluff, MO 63901-1908 Ph: (573) 686-3937 | Imran Q Cheema, MD 2620 N Westwood Blvd, Poplar Bluff, MO 63901-3396 Ph: (573) 686-3937 |
News Archive
A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.
Researchers for Action for Children in a survey of over 3,000 eight to 12 year-olds found that 44% of children under 12 have seen other children who were dirty and smelled. Nearly two-thirds of children have seen suspected signs of neglect among their peers in classrooms, playgrounds, neighborhoods and activity clubs.
Millions of people around the world use acid suppressants called proton pump inhibitors for conditions like heartburn, gastritis and stomach ulcers. Researchers at Karolinska Institutet in Sweden now report that how the long-term use of these drugs could increase the risk of developing dementia.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
› Verified 6 days ago
Mrs. Philma Balite Opinaldo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 225 Physicians Parkway, Suite 303, Poplar Bluff, MO 63901 Phone: 573-785-6536 Fax: 573-785-0345 | |
Hanumanth K Reddy, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3100 Oak Grove Rd, Poplar Bluff, MO 63901 Phone: 573-776-2600 | |
Steven S. Smith, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 N Westwood Blvd, Poplar Bluff, MO 63901 Phone: 573-339-0909 | |
Lance T Majors, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 225 Physicians Park Ste 400, Poplar Bluff, MO 63901 Phone: 573-727-5500 Fax: 573-727-5599 | |
Khalil J Haiderzad, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 N Westwood Blvd, John J Pershing Vamc, Poplar Bluff, MO 63901 Phone: 573-778-4441 | |
Sehrish Khan, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3100 Oak Grove Rd, Poplar Bluff, MO 63901 Phone: 573-776-2000 | |
Dr. Dennis Edwards Daniels, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1906a Greenwood Dr, Poplar Bluff, MO 63901 Phone: 573-778-5913 Fax: 573-776-7750 |